AG
NAMS icon

Artal Group’s NewAmsterdam Pharma NAMS Stock Holding History

Artal Group’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-800,000
Closed -$15.4M – 61
2024
Q2 		$15.4M Hold
800,000
– – 0.39% 28
2024
Q1 		$18.9M Buy
+800,000
New +$16.2M 0.48% 28

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Artal Group's NAMS Position: Q3 2024 in Review

Artal Group sold out of NewAmsterdam Pharma (NAMS) in Q3 2024, closing a stake of 800,000 shares — an estimated $15.4M sold.

Artal Group first reported a position in NAMS in Q1 2024 and held it in 2 quarters. The position peaked at $18.9M in Q1 2024. 100 funds tracked by Wall St. Rank hold NAMS as of Q3 2024.

  • Artal Group reported no remaining NewAmsterdam Pharma position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 800,000 NewAmsterdam Pharma shares in Q3 2024, an estimated $15.4M.
  • Artal Group first reported a position in NewAmsterdam Pharma in Q1 2024 and held it in 2 quarters.
  • Artal Group's NewAmsterdam Pharma position peaked at $18.9M in Q1 2024.
  • 100 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.